Oncovista Innovative Therapies Inc
OTC:OVIT
Income Statement
Earnings Waterfall
Oncovista Innovative Therapies Inc
Income Statement
Oncovista Innovative Therapies Inc
| Dec-2008 | Mar-2009 | Jun-2009 | Sep-2009 | Dec-2009 | Mar-2010 | Jun-2010 | Sep-2010 | Dec-2010 | Mar-2011 | Jun-2011 | Sep-2011 | Dec-2011 | Mar-2012 | Jun-2012 | Sep-2012 | Dec-2012 | Mar-2013 | Jun-2013 | Sep-2013 | Dec-2013 | Mar-2014 | Jun-2014 | Sep-2014 | Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
1
N/A
|
1
+20%
|
1
+33%
|
1
+19%
|
0
N/A
|
1
N/A
|
1
-35%
|
0
-45%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||||||
| Operating Expenses |
(9)
|
(8)
|
(7)
|
(7)
|
(4)
|
(4)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
| Selling, General & Administrative |
(5)
|
(5)
|
(5)
|
(4)
|
(2)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(3)
|
(3)
|
|
| Research & Development |
(3)
|
(3)
|
(3)
|
(3)
|
(1)
|
(2)
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
| Operating Income |
(8)
N/A
|
(7)
+7%
|
(6)
+13%
|
(6)
+12%
|
(4)
+31%
|
(4)
+9%
|
(3)
+27%
|
(2)
+19%
|
(2)
-13%
|
(2)
-1%
|
(2)
0%
|
(3)
-7%
|
(2)
+16%
|
(2)
-1%
|
(2)
-1%
|
(2)
+9%
|
(2)
+3%
|
(2)
+5%
|
(2)
+12%
|
(2)
+8%
|
(2)
+1%
|
(1)
+9%
|
(1)
+4%
|
(1)
+4%
|
(3)
-101%
|
(3)
-1%
|
(3)
-31%
|
(3)
-1%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||
| Interest Income Expense |
1
|
1
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(0)
|
0
|
0
|
1
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(7)
N/A
|
(7)
+9%
|
(7)
+4%
|
(6)
+12%
|
(4)
+30%
|
(3)
+13%
|
(3)
+21%
|
(2)
+18%
|
(2)
-2%
|
(3)
-23%
|
(3)
+4%
|
(2)
+11%
|
(2)
+8%
|
(2)
+4%
|
(2)
+15%
|
(2)
-5%
|
(2)
+15%
|
(1)
+13%
|
(1)
-1%
|
(1)
N/A
|
(1)
-1%
|
(1)
+9%
|
(2)
-48%
|
(1)
+31%
|
(3)
-88%
|
(3)
+1%
|
(3)
-8%
|
(3)
-20%
|
|
| Net Income | |||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(7)
|
(7)
|
(7)
|
(6)
|
(4)
|
(3)
|
(3)
|
(2)
|
(2)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(7)
N/A
|
(7)
+9%
|
(7)
+4%
|
(6)
+12%
|
(5)
+16%
|
(4)
+27%
|
(3)
+20%
|
(2)
+13%
|
10
N/A
|
10
-4%
|
10
+1%
|
10
+4%
|
(2)
N/A
|
(2)
+4%
|
(2)
+17%
|
(2)
-6%
|
(2)
+5%
|
(1)
+13%
|
(1)
-1%
|
(1)
N/A
|
(1)
-1%
|
(1)
+9%
|
(2)
-48%
|
(1)
+31%
|
(3)
-88%
|
(3)
+1%
|
(3)
-8%
|
(3)
-20%
|
|
| EPS (Diluted) |
-0.41
N/A
|
-0.36
+12%
|
-0.35
+3%
|
-0.31
+11%
|
-0.25
+19%
|
-0.19
+24%
|
-0.14
+26%
|
-0.11
+21%
|
0.49
N/A
|
0.47
-4%
|
0.45
-4%
|
0.47
+4%
|
-0.1
N/A
|
-0.1
N/A
|
-0.08
+20%
|
-0.09
-12%
|
-0.08
+11%
|
-0.07
+12%
|
-0.07
N/A
|
-0.07
N/A
|
-0.07
N/A
|
-0.06
+14%
|
-0.09
-50%
|
-0.06
+33%
|
-0.12
-100%
|
-0.11
+8%
|
-0.12
-9%
|
-0.15
-25%
|
|